Kura Oncology (NASDAQ:KURA) Stock Price Down 7.6% – Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) fell 7.6% during mid-day trading on Monday . The company traded as low as $6.56 and last traded at $6.52. 240,598 shares were traded during mid-day trading, a decline of 78% from the average session volume of 1,089,767 shares. The stock had previously closed at $7.05.

Wall Street Analysts Forecast Growth

KURA has been the topic of several research reports. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Scotiabank reduced their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. JMP Securities reiterated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. UBS Group decreased their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Trading Down 0.2 %

The stock has a market capitalization of $514.41 million, a P/E ratio of -2.70 and a beta of 0.85. The stock’s fifty day moving average price is $7.79 and its 200 day moving average price is $11.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 over the last quarter. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after buying an additional 1,750 shares during the last quarter. Rhumbline Advisers boosted its position in Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after purchasing an additional 1,923 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock worth $120,000 after purchasing an additional 2,285 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Kura Oncology by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock worth $390,000 after buying an additional 2,776 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.